MAPT and tauopathy: This result is expected, given that Aβ drives tau aggregation, which in turn drives neurodegeneration and cognitive decline;3, 4, 20, 21, 22 hence, therapeutic removal of Aβ should ideally take place prior to tauopathy onset to prevent neurodegeneration and cognitive decline.